The Rise of GLP-1 Medications: Are We Treating the Symptom Instead of the Cause?
Over the past two years, medications such as Ozempic, Wegovy and Mounjaro have become household names. Originally designed to support people with type 2 diabetes, these longer-acting GLP-1 agonists are now widely used for weight loss and appetite control.
As a nutritionist, I’m seeing an increasing number of clients who are currently taking these medications, have tried them in the past, or are considering them after seeing dramatic transformations online. Some experience rapid weight loss, while others struggle with nausea, bloating, digestive discomfort, fatigue, muscle loss, or disappointing results altogether.
The growing popularity of these medications says a lot about the world we now live in. We are surrounded by messages promising fast results, quick fixes, and instant gratification. Social media has conditioned us to expect immediate outcomes, whether that’s overnight success, same-day delivery, or dramatic body transformations in a matter of weeks.
But when it comes to our health, the human body doesn’t work that way.
Why Are So Many People Turning to GLP-1 Medications?
The truth is, many people are exhausted.
They’re overwhelmed, stressed, undernourished, time-poor, and trying to navigate a food environment that has changed dramatically over the last few decades. Highly processed convenience foods are more accessible than ever, while whole foods are becoming increasingly nutrient depleted.
In Australia particularly, our farming systems have intensified significantly. Soil depletion, over-farming, and long transport times mean many “fresh” foods contain fewer nutrients than they once did. By the time produce reaches supermarket shelves, it may have travelled thousands of kilometres and spent days, sometimes weeks, in storage.
At the same time:
Ultra-processed foods dominate supermarket aisles
Busy lifestyles push people toward convenience eating
Sedentary lifestyles are increasingly common
Chronic stress impacts sleep, hormones, appetite, and metabolism
Rates of obesity, insulin resistance, and type 2 diabetes continue to rise
Instead of addressing these root causes, society is increasingly leaning toward pharmaceutical solutions.
And while these medications absolutely have a place in modern medicine, they are not a complete solution for the broader population.
How Do GLP-1 Medications Work?
GLP-1 receptor agonists mimic a naturally occurring hormone called glucagon-like peptide-1. These medications help:
Slow stomach emptying
Reduce appetite
Increase feelings of fullness
Improve blood sugar regulation
Reduce food cravings in some individuals
This can lead to significant weight loss, especially when combined with dietary and lifestyle changes.
Newer medications such as tirzepatide (the active ingredient in Mounjaro) target both GLP-1 and GIP receptors, which appears to enhance weight-loss effects further. Research published in 2024 found tirzepatide produced greater weight loss than semaglutide in adults with overweight or obesity.
What Does the Research Actually Show?
There’s no denying these medications can be highly effective for some individuals.
A 2024 meta-analysis examining tirzepatide found significant reductions in body weight in adults with obesity and type 2 diabetes.
A large observational study published in JAMA Internal Medicine reported that many patients using semaglutide or tirzepatide achieved clinically meaningful weight loss within 12 months. However, the same study also found that more than 50% of participants discontinued the medication within a year.
Australian data is also beginning to emerge. A recent real-world Australian study involving more than 4,000 participants using tirzepatide through a digital weight-loss program showed meaningful weight loss outcomes among adherent users. However, long-term adherence dropped substantially over time.
This highlights something important:
Weight loss alone does not necessarily equal long-term health transformation.
The Side Effects Many People Aren’t Prepared For
One of the biggest concerns I’m seeing clinically is the number of people experiencing digestive discomfort and nutritional challenges while taking these medications.
Common side effects include:
Nausea
Constipation
Diarrhoea
Bloating
Vomiting
Fatigue
Reduced appetite to the point of under-eating
Muscle loss due to inadequate protein intake
Emerging research is also raising questions about lean muscle loss during rapid weight reduction. Some studies suggest a significant portion of weight lost on GLP-1 medications may come from lean body mass if adequate nutrition and resistance training are not prioritised.
This is where proper nutritional support becomes essential.
If someone is eating very little, skipping meals, or relying on processed “diet foods” while taking these medications, they may lose weight but they may also compromise muscle mass, nutrient intake, metabolic health, digestive function, and long-term sustainability.
The Bigger Problem We Need to Address
Medications can suppress appetite.
They cannot teach someone:
How to nourish their body properly
How to build sustainable habits
How to regulate stress
How to improve sleep
How to create balanced meals
How to reconnect with hunger and fullness cues
How to support their metabolism long term
Without this foundation, many people find themselves returning to previous habits once the medication stops, often regaining weight and feeling like they’ve “failed”.
But this isn’t a failure of willpower.
It’s a reflection of the environment we’ve created.
We live in a society that normalises:
Processed foods over real food
Convenience over nourishment
Stress over rest
Restriction over education
Quick fixes over sustainable change
A More Balanced Approach
GLP-1 medications are not inherently “good” or “bad”.
For some individuals, particularly those with type 2 diabetes, severe insulin resistance, or significant obesity-related health complications they can be life-changing tools when used appropriately and under medical supervision.
But they work best when paired with:
Nutritional education
Whole-food foundations
Adequate protein intake
Resistance training
Sleep support
Stress management
Long-term behaviour change
The goal shouldn’t simply be weight loss.
The goal should be improving overall health, energy, metabolic function, confidence, and quality of life in a way that is sustainable beyond a prescription.
Final Thoughts
There is no quick fix for long-term health.
While medications like Ozempic, Wegovy, and Mounjaro may offer short-term appetite suppression and weight loss, they do not address the deeper reasons so many people are struggling with their health in the first place.
Our modern food environment, nutrient depletion, stress levels, lifestyle habits, and disconnection from whole-food nutrition all play a role.
Real health transformation requires education, support, consistency, and a willingness to look beyond the latest trend.
Because lasting health is not built in a syringe it’s built through the daily habits we return to over and over again.
References
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W. Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., & Stefanski, A. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Kadowaki, T., Isendahl, J., Khalid, U., Lee, Y. C., Nishida, T., Ogawa, W., & Arao, T. (2023). Semaglutide in adults with overweight or obesity: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 25(1), 18–28. https://doi.org/10.1111/dom.14863
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Yuan, Q., Huang, Z., Lin, W., & Chen, H. (2024). Efficacy and safety of tirzepatide for weight management in overweight or obese adults: A systematic review and meta-analysis. Endocrine, 84(2), 312–324. https://doi.org/10.1007/s12020-024-03896-z